利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.025 秒)

    CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS
    4.
    发明公开
    CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS 审中-公开
    GLUCAGON和GLP-1受体的共同激动剂

    公开(公告)号：EP3209682A1

    公开(公告)日：2017-08-30

    申请号：EP15790398.0

    申请日：2015-10-22

    申请人： Merck Sharp & Dohme Corp.

    发明人： CARRINGTON, Paul, E. ,  DENG, Qiaolin ,  NARGUND, Ravi ,  PALANI, Anandan ,  TUCKER, Thomas Joseph ,  WU, Chengwei ,  BIANCHI, Elisabetta ,  ORVIETO, Federica ,  PESSI, Antonello

    IPC分类号： C07K14/605 ,  A61K38/26 ,  A61K38/28

    CPC分类号： A61K38/28 ,  A61K38/26 ,  C07K14/605 ,  A61K2300/00

    摘要： Described are peptide analogs of glucagon, which have been modified to be resistant to cleavage and inactivation by dipeptidyl peptidase IV (DPP-IV) and to increase in vivo half-life of the peptide analog while enabling the peptide analog to have relatively balanced agonist activity at the glucagon-like peptide 1 (GLP-1) receptor and the glucagon (GCG) receptor, and the use of such GLP-1 receptor/GCG receptor co-agonists for treatment of metabolic disorders such as diabetes, non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and obesity

    摘要翻译： 描述了胰高血糖素的肽类似物，其已经被修饰以抵抗二肽基肽酶IV（DPP-IV）的切割和失活并且增加肽类似物的体内半衰期，同时使肽类似物具有相对平衡的激动剂活性 对胰高血糖素样肽1（GLP-1）受体和胰高血糖素（GCG）受体的应用，以及此类GLP-1受体/ GCG受体共激动剂用于治疗代谢病症例如糖尿病，非酒精性脂肪肝 疾病（NAFLD），非酒精性脂肪性肝炎（NASH）和肥胖。